FDA Seizes Counterfeit Ozempic in U.S. Supply Chain

The FDA and Novo Nordisk are investigating the safety of fake Ozempic products following reports of adverse events.

The FDA confiscated several hundred units of counterfeit 1-milligram Ozempic injections on April 9, 2025, after Novo Nordisk flagged their presence in the U.S. supply chain.
The counterfeit products were identified with lot number PAR0362 and specific serial numbers, likely entering the market through unauthorized distributors or resellers.
Six adverse event reports have been linked to the lot, though none are confirmed to involve the counterfeit drugs; safety testing is ongoing.
This seizure follows a larger December 2023 incident where thousands of fake Ozempic units were discovered, highlighting persistent challenges with counterfeit drugs.
The FDA has advised patients and healthcare providers to verify the authenticity of Ozempic prescriptions to ensure safety and effectiveness.